Memantine in severe dementia, results of the 9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)

International Journal of Geriatric Psychiatry

Volumn 14, Issue 2, 1999, Pages 135-146

  Winblad, B ^a   Poritis, N ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Latvian Study Group   (Latvia)

Author keywords

Alzheimer's disease; BGP; D Scale; Dementia; Drug effects; Glutamate modulator; Memantine; Nmda antagonist; Vascular dementia

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ADULT; AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DEPENDENT PERSONALITY DISORDER; DRUG SAFETY; FEMALE; FEVER; GERONTOPSYCHIATRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VOMITING;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; DEMENTIA, VASCULAR; DISABLED PERSONS; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; SELF CARE; TREATMENT OUTCOME;

EID: 0032983786     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0     Document Type: Conference Paper

References (38)

1. American Psychiatric Association (ed.) (1987) Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R. APA, Washington DC.
2. Arnold, K., Lehfeld, H., Mösler, Th. and Erzigkeit, H. (1998) Scale properties of the D-scale in severe dementia. 6th Int. Cong. Alzheimer's Dis. 18-23 July, Amsterdam.
3. Bormann, J. (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. European J. Pharmacol. 166, 591-592.
4. Bundesgesundheilsamt (1991) Empfehlungen zum Wirksamkeitsnachweis von Nootropika im Indikationsbereich "Demenz" (Phase III). Gemeinsames Papier der das Bundesgesundheitsamt beratenden Zulassungskommission für neue Stoffe (Kommission A) und der Aufbereitungskommission "Neurologie, Psychiatrie" (Kommission B3). Bundesgesundheitsblatt 7, 342-350.
5. Clinical Research Working Group from the Pharmaceutical Industry on Dementia (Dahlke, F. et al. 1990) Recommendations for clinical drug trials in dementia. Dementia 1, 292-295.
6. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease. The European Agency for the Evaluation of Medicinal Products CPMP/EWP/553/95. 27 July 1997, London.
7. Diesfeldt, H. F. A. (1980) Gedragsobservaties, psychologisch oderzoek en overleving na een jaar bij psychogeriatrische patienten. Gerontologie 11, 205-212.
8. Ditzler, K. (1991) Efficacy and tolerability of Memantine in patients with dementia syndrome. A double-blind, placebo-controlled trial. Arzneimittel-Forschung Drug Res. 41(II, 8), 773-780.
9. Ferm, L. (1974) Behavioural activities in demented geriatric patients. Geront. Clin. 16, 185-194.
10. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 12, 189-198.
11. Francis, P. T., Simms, N. R., Proctor, A. W. and Bowen, D. M. (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease - investigative and therapeutic perspectives. J. Neurochem. 60, 1589-1604.
12. Franssen, E. H., Reisberg, B., Kluger, A., Sinaike, E. and Boja, C. (1991) Cognition-independent neurologic symptoms in normal ageing and probable Alzheimer's disease. Arch. Neurol. 48, 148-154.
13. Görtelmeyer, R. and Erbler, H. (1992) Memantine in treatment of mild to moderate dementia syndrome. Drug Res. 42, 904-913.
14. Greenamyre, J. T., Maragos, E. F., Albin, R. L., Penney, J. B. and Young, A. B. (1988) Glutamate transmission of toxicity in Alzheimer's disease. Prog. Neuro-Psych. Biol. Psych. 12, 421-430.
15. Hamilton, M. (1960) A rating scale for depression. J. Neurol. Neurosurg. Psychiat. 23, 56-62.
16. Herrmann, W. M. and Kern, U. (1987) Nootropic drugs. Effects and therapeutic efficacy. A phase II study with piracetam as a model. Nervenarzt. 58, 358-364.
17. Herrmann, W. M. and Schärer, E. (1988) Wirkungen und wirksamkeit von nootropica (Effects and efficacy of notropics). In Wirkungen und Wirksamkeit von Nootropica H. Helmchen (Ed.) Springer, Berlin, pp. 71-92.
18. Herrmann, W. M. and Stephan, K. (1992) Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 in-patients with dementia syndrome taking piracetam. Int. Psychogeriatr. 4, 25-44.
19. van der Kam, P. and Hoeksma, B. H. (1989) The usefulness of BOP and SIVIS (ADL and behaviour rating scales) for the estimation of workload in psychogeriatric nursing home. Results of a time-standard study. Tijdschr. Gerontol. Geriatr. 20, 159-166.
20. van der Kam, P., Mol, F. and Wimmers, M. F. H. C. (1971) Beoordelingsschaal voor oudere patienten (BOP). Van Loghum Slaterus, The Netherlands.
21. Kornhuber, J., Bormann, J., Retz, W., Hübers, M. and Riederer, P. (1989) Memantine displaces [3H] MK-801 at therapeutic concentrations in post mortem human frontal cortex. Eur. J. Pharmacol. 166, 589.
22. Li, S., Mallory, M., Alford, M., Tanaka, S. and Masliah, E. (1997) Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56, 901-911.
23. van Loo, E. H., Roelofs, C. A. and Diesfeldt, H. F. A. (1990) Veranderingen in hulpbehoevendheld bij patienten in eenpsychogeriatrisch verpleeghuis, bi eerst opname enop peildata. Tijdschr. Gerontol. Geriatr. 21, 61-66.
24. Misztal, M., Frankiewicz, T., Parsons, C. G. and Danysz, W. (1996) Learning deficits induced by chronic intraventricular infusion of quinoclinic acid-protection by MK-801 and memantine. Eur. J. Pharmacol. 296, 1-8.
25. Müller, W. E., Mutschler, E. and Riederer, P. (1995) Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 28, 113-124.
26. National Institute of Mental Health (1986) 028 CGI. Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology (W. Guy Ed.) Rockville, Maryland, pp. 217-222.
27. Palmer, A. M. and Gershon, S. (1990) Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4, 2745-2752.
28. Parsons, C. G., Gruner, R., Rosental, J., Millar, J. and Lodge, D. (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by Memantine (1-amino-3.5-dimethyladamantan). Neuropharmacologv 32, 1337-1350.
29. Pantev, M., Ritter, R. and Görtelmeyer, R. (1993) Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Zeitschrift für Gerontopsychologie und -psychiatrie 6, 103-117.
30. Reisberg, B., Ferris, S. H., de Leon, M. J. and Crook, T. (1982) The global deterioration scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD). Am. J. Psychiat. 139, 1136-1139.
31. Rosen, W. G., Terry, R. D., Fuid, P. A., Katzmann, R. and Peck, A. (1980) Pathological verification of ischaemic score in differentiation of dementias. Ann. Neurol. 7, 486-488.
32. Souren, L. E. M., Franssen, E. H. and Reisberg, B. (1995) Contractures and loss of function in patients with Alzheimer's disease. JAGS 43, 650-655.
33. Spiegel, R., Brunner, Ch., Ermini-Fünfschilling, D., Monsch, A., Notter, M., Puxty, J. and Tremmel, L. (1991) A new behavioural assessment scale for geriatric out-and in-patients: the NOSGER (Nurses Observation Scale for Geriatric Patients). J. Amer. Geriatr. Soc. 39, 339-347.
34. Tempel, D. (1989) Memantine in organic brain syndrome. Therapiewoche 39, 948-952.
35. Wenk, G. L., Danysz, W. and Roice, D. D. (1996) The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport 7, 1453-1456.
36. Weyer, G. (1992) Methodologische Überlegungen zur Betimmung von Therapierespondern in Nootropikastudien. In Pharmakopsychologie (J. Oldigs-Kerber and Leonard Eds). Fisher Verlag, Jena.
37. Zajaczkowski, W., Frankiewicz, T., Parsons, C. G. and Danysz, W. (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36, 961-971.
38. Zajaczkowski, W., Quack, G. and Danysz, W. (1996) Infusion of (+)-MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296, 239-246.